Literature DB >> 9307256

Short- and long-duration responses to levodopa during the first year of levodopa therapy.

J G Nutt1, J H Carter, L Van Houten, W R Woodward.   

Abstract

We examined the response to 2-hour levodopa infusions in 18 Parkinson's disease subjects before starting long-term levodopa treatment and after 6 and 12 months of treatment using tapping speed as an index of bradykinesia. The long-duration response (LDR), measured as the increase in baseline (overnight without levodopa) tapping speed, increased by 29 +/- 18 at 6 months and by 35 +/- 24 at 12 months. The magnitude of the short-duration response (SDR) to a 2-hour levodopa infusion after an overnight levodopa withdrawal did not differ at 6 and 12 months (16 +/- 8 and 20 +/- 13 taps/min) from that before long-term levodopa (21 +/- taps/min). However, when levodopa was withheld for 3 days, it was evident that the SDR magnitude was increasing in magnitude (19, 23, and 31 taps/min at 0, 6, and 12 months). Duration of SDR did not change. A diurnal motor pattern with faster tapping speeds in the morning and slower in the evening was apparent on the days no levodopa was administered. These observations indicate (1) the LDR is responsible for much of the sustained response to levodopa during the first year of treatment, (2) the SDR magnitude increases but is obscured by the LDR, and (3) a diurnal pattern of motor function is present that may be partially responsible for the poorer motor function in the afternoons and evenings.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307256     DOI: 10.1002/ana.410420311

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  27 in total

1.  Dopamine-dependent motor learning: insight into levodopa's long-duration response.

Authors:  Jeff A Beeler; Zhen Fang Huang Cao; Mazen A Kheirbek; Yunmin Ding; Jessica Koranda; Mari Murakami; Un Jung Kang; Xiaoxi Zhuang
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

Review 2.  Preservation of function in Parkinson's disease: what's learning got to do with it?

Authors:  Jeff A Beeler
Journal:  Brain Res       Date:  2011-09-29       Impact factor: 3.252

3.  Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-06       Impact factor: 2.745

4.  Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

6.  A role for dopamine-mediated learning in the pathophysiology and treatment of Parkinson's disease.

Authors:  Jeff A Beeler; Michael J Frank; John McDaid; Erin Alexander; Susie Turkson; Maria Sol Bernardez Sarria; Maria Sol Bernandez; Daniel S McGehee; Xiaoxi Zhuang
Journal:  Cell Rep       Date:  2012-12-13       Impact factor: 9.423

7.  [A biomechanical analysis of cyclical hand motor function: a pilot study in different Parkinsonian syndromes].

Authors:  T Wolfsegger; I Rotaru; R Topakian; R Pichler; M Sonnberger; F T Aichner; H Schwameder
Journal:  Nervenarzt       Date:  2012-06       Impact factor: 1.214

Review 8.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

Review 9.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

10.  Medical decision making for patients with Parkinson disease under Average Cost Criterion.

Authors:  John E Goulionis; Athanassios Vozikis
Journal:  Aust New Zealand Health Policy       Date:  2009-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.